Date: 13-Nov-2019

Novartis GDD Centre in Hyderabad to support critical components of drug development process for patient safety

Novartis global drug development (GDD) Centre in Hyderabad has chalked out a strategy to support critical components of the drug development process across Novartis’ drug pipeline for patient safety. This includes Novartis integrated pipeline like innovative medicines for cancer treatments, generics and biosimilars. Novartis GDD Centre in Hyderabad has enhanced its focus on development programmes to determine and establish safety and efficacy of a potential new medicine in humans through clinical trials. GDD India also plays a critical role in enabling Novartis strategy to bring life-saving medicines to market including breakthrough products such as the heart failure treatment Entresto (sacubitril/valsartan), Cosentyx (secukinumab, AIN457) and Kisqali (ribociclib, LEE011). All of these breakthrough products are being made available to patients in India. “Technical, analytical research and development work is carried out at GDD Centre which also includes testing and analysis of drug formulations. Being a government recognized research and development centre, it also plays a critical role in Novartis’ global strategy to bring life-saving medicines to market by supporting regulatory filings,” explains Arno Tellmann, head, Novartis GDD India. He further adds, “The centre plays a key role in Novartis’ global vision of combining deep therapeutic area knowledge with advanced, integrated data analytics to drive an agile approach to drug development.” The GDD Hyderabad site has state-of-the-art lab facilities as well as integrated development capabilities with a strong operational footprint across all major drug development functions. It also has the added advantage of housing key drug development functions under one roof. This has resulted in enhanced collaboration internally as well as with Hyderabad’s thriving innovation ecosystem. “Safeguarding the patient during the clinical trials process is paramount. When it comes to clinical trials, we have checks and measures at every step starting with informed consent. The candidate has to undergo a thorough health check-up to minimize the possibility of any adverse event. She/he is made fully aware of all the steps and processes involved,” informs Tellmann.